1. Home
  2. VHC vs BOLD Comparison

VHC vs BOLD Comparison

Compare VHC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

N/A

Current Price

$9.89

Market Cap

46.0M

Sector

Miscellaneous

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.50

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VHC
BOLD
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
46.0M
54.5M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
VHC
BOLD
Price
$9.89
$2.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.6K
★ 138.7K
Earning Date
11-20-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
0.99
★ 32.47
EPS
N/A
★ N/A
Revenue
★ $162,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3140.00
N/A
52 Week Low
$8.41
$0.96
52 Week High
$25.83
$3.16

Technical Indicators

Market Signals
Indicator
VHC
BOLD
Relative Strength Index (RSI) 42.48 48.06
Support Level $8.50 $2.43
Resistance Level $11.33 $2.65
Average True Range (ATR) 0.63 0.10
MACD 0.00 0.01
Stochastic Oscillator 39.34 45.10

Price Performance

Historical Comparison
VHC
BOLD

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. Its software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: